RAPTOR METALS LTD
No trades
What traders are saying
RAP | weekly trend continuation, 4hr consolidation ~ completehey traders,
looking at RAP to have completed/almost completed a 4hrly consolidation suggesting the continuation of an uptrend. i am in.
trade safe,
MIC.
Resapp Health Ltd: RAP.AXWatchlist
Price moving out of downtrend
Base being built
All EMA's tightening up, a move looks pretty close
Only issue I see here is that there is no volume
Keep an eye on the 18.5c level
Watch for any increase in volume
RAP | weekly flat pattern potential hey traders,
looking at this company for a long opportunity.
regards,
tm
ASX:RAP - Fundamentally strong, technically neutralASX:RAP is an interesting combination of strong fundamentals and filthy price action. Purely technical traders may be deterred, however under the hood we're presented with some interesting insights that might be overlooked by those without intimate knowledge of the company.
Technicals - Neutral
Reasons to take a trade:
Location: Using the most recent swing point, we're at the 0.786.
Structure: Double bottom formed.
Divergence: Unconfirmed histogram bullish div, healthy OBV.
Flip of previous resistance zone into support.
Trading above the 200MA.
Areas of concern:
Gaps gaps gaps! As a trader, I get nervous when I'm buying above so many unfilled gaps.
The VPVR POC is resting down at 0.090, with thin volume below current PA.
Fundamentals - Bullish
FDA approval is looking to come through likely this month (Feb 2020) otherwise next, its above average length of approval, however no further questions have come back from FDA since mid/late last year and Feb is historically when FDA starts approving again after the holiday break.
Healthy books and cash balance to see company through to end of CY20 and likely revenue generation.
Sanofi startup accelerator is coming to close this week with final presentations, noting Sanofi has option to exercise its rights to ResApp products until March.
Coviou App integration negotiations will be complete by end of March (End of Nov accouned with 4 month timeline)
COPD Trial to commence after ethical approval.
Continued work on Lockheed Martin in background.
Hit the LIKE button if you find my analysis valuable and want to support me. Follow to make sure you don't miss any future trade ideas.
Looks like ASX:RAP is on the move again.Time to look @ renteringI've probably held this one back a little longer than I would normally, due to my personal bias of previously being burnt by it...But the charts are now too interesting to leave it in my watch list. If your not familiar with ASX:RAP they are producing a smart phone App to help diagnose respiratory conditions. Some recent news around TGA classification as a medical device has helped spur the price northward and it's now time for me to face my demons...
If you remain unconvinced, perhaps add it to your watch list...
Disclaimer: We do not currently hold this stock.
$RAP:ASX - RESAPP HEALTH - Up 250% YTDMight be a bit overbought at the moment looking at the RSI, but it is still trading with the upper bollinger and demand is high with 269 buyers for 12,650,445 units vs 80 sellers for 2,279,491 units. Might be worth a watch.
ResApp Health Limited is engaged in developing digital healthcare solutions to assist doctors and patients to diagnose and manage respiratory disease. The Company offers a range of solutions, such as telehealth, clinical use, direct consumer and big data insights. The Company provides point of care diagnostic solutions for telehealth companies, which is integrated into their platforms. The Company is working on applications to provide clinical quality diagnostic tests and management tools directly to consumers and healthcare providers. The Company is developing smartphone medical applications for the diagnosis and management of respiratory disease. The Company's technology is based on the premise that cough and breathing sounds carry vital information on the state of the respiratory tract. ResApp measures the severity of a range of chronic and acute diseases, such as pneumonia, asthma, bronchiolitis and chronic obstructive pulmonary disease (COPD) using this insight.
